By Alice Miranda Ollstein and Josh Gerstein

The challenge concerning Idaho hospitals’ obligation to provide abortions during medical emergencies would have national ripple effects.

A decision, likely to come in June, would be a major victory for the FDA’s authority to regulate prescription drugs and for abortion-rights advocates who have sought to protect access to mifepristone.

This is the first major reproductive-rights case to come before the court since the 2022 Dobbs ruling, which ended the federal right to abortion.

A decision, likely to come in June, would be a major victory for the FDA’s authority to regulate prescription drugs and for abortion-rights advocates who have sought to protect access to mifepristone.

This is the first major reproductive-rights case to come before the court since the 2022 Dobbs ruling, which ended the federal right to abortion.

A decision, likely to come in June, would be a major victory for the FDA’s authority to regulate prescription drugs and for abortion-rights advocates who have sought to protect access to mifepristone.

This is the first major reproductive-rights case to come before the court since the 2022 Dobbs ruling, which ended the federal right to abortion.

A decision, likely to come in June, would be a major victory for the FDA’s authority to regulate prescription drugs and for abortion-rights advocates who have sought to protect access to mifepristone.

This is the first major reproductive-rights case to come before the court since the 2022 Dobbs ruling, which ended the federal right to abortion.

A decision, likely to come in June, would be a major victory for the FDA’s authority to regulate prescription drugs and for abortion-rights advocates who have sought to protect access to mifepristone.

This is the first major reproductive-rights case to come before the court since the 2022 Dobbs ruling, which ended the federal right to abortion.

A decision, likely to come in June, would be a major victory for the FDA’s authority to regulate prescription drugs and for abortion-rights advocates who have sought to protect access to mifepristone.

This is the first major reproductive-rights case to come before the court since the 2022 Dobbs ruling, which ended the federal right to abortion.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

During a two-hour oral argument, the judges appeared sympathetic to an anti-abortion medical group seeking to revoke the FDA’s approval of mifepristone.

Top Republicans in other states say they are examining how the Texas law’s unique “private right of action” enforcement structure could be used for similar abortion bans.

Top Republicans in other states say they are examining how the Texas law’s unique “private right of action” enforcement structure could be used for similar abortion bans.